Menu Close

R&D tax credit claims, rebates & refunds in the pharmaceutical sector

These examples illustrate the diverse range of R&D tax credit claims, rebates & refunds in the pharmaceutical sector to drive innovation, advance scientific knowledge, and bring new therapies to market to improve patient outcomes and public health.

Drug Discovery: Conducting research to discover and develop new pharmaceutical compounds, including small molecules, biologics, and gene therapies, for the treatment and prevention of diseases ranging from cancer and infectious diseases to chronic conditions like diabetes and cardiovascular diseases.

Preclinical Studies: Performing preclinical studies, including in vitro assays and animal testing, to evaluate the safety, efficacy, and pharmacokinetics of potential drug candidates, identify lead compounds, and optimize drug formulations before advancing to clinical trials.

Clinical Trials: Designing and conducting clinical trials to assess the safety and efficacy of investigational drugs in human subjects, including Phase I trials for safety, Phase II trials for efficacy, and Phase III trials for confirmatory evidence of effectiveness prior to regulatory approval.

Biopharmaceutical Manufacturing: Developing manufacturing processes and technologies for the production of biopharmaceuticals such as monoclonal antibodies, recombinant proteins, and cell-based therapies, including cell culture systems, purification techniques, and bioreactor design.

Drug Delivery Systems: Innovating drug delivery systems and technologies, including oral formulations, injectables, transdermal patches, and targeted drug delivery systems, to improve drug bioavailability, stability, and patient compliance while minimizing side effects and adverse reactions.

Personalized Medicine: Researching and developing personalized medicine approaches, including biomarker identification, genetic testing, and companion diagnostics, to tailor treatment strategies to individual patient characteristics, genotypes, and disease profiles for improved therapeutic outcomes.

Pharmacovigilance and Drug Safety: Monitoring and evaluating the safety profile of marketed drugs through pharmacovigilance activities such as adverse event reporting, risk assessment, and post-market surveillance to ensure patient safety and regulatory compliance.

Health Economics and Outcomes Research: Conducting health economics and outcomes research (HEOR) studies to assess the cost-effectiveness, comparative effectiveness, and real-world outcomes of pharmaceutical interventions, informing healthcare decision-making and reimbursement policies.

Regulatory Affairs and Compliance: Ensuring compliance with regulatory requirements and guidelines governing the development, manufacturing, and marketing of pharmaceutical products, including submission of regulatory filings, interactions with regulatory agencies, and pharmacovigilance reporting.

Collaborative Research Partnerships: Collaborating with academic institutions, research organizations, and biotechnology companies on collaborative R&D projects, technology licensing agreements, and strategic partnerships to advance drug discovery and development efforts.

 


Discover more from AI R&D Tax Credit Claims

Subscribe to get the latest posts to your email.